去纤苷适用于什么病症呢？

Defibrotide (defiteli) is an effective drug suitable for the treatment of hepatic veno-occlusive disease. Hepatic veno-occlusive disease (HVOD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), and the mortality rate in patients with severe HVOD can be as high as 100%. Defibrotide (defiteli) is a single-stranded oligonucleotide mixture that has anti-thrombotic and fibrinolytic effects.

In recent years, multiple clinical research results have shown that defibrotide (defiteli) is a safe and effective drug for preventing and treating HVOD after HSCT; defibrotide (defiteli) was first developed by Gentium Pharmaceuticals in Italy and was approved for marketing in the EU in October 2013. After Gentium Pharmaceuticals was acquired by Jazz Pharmaceuticals of the United States, defiteli (defiteli) was approved by the US Food and Drug Administration (FDA) to be launched in the United States on March 30, 2016, under the trade name Defitelio.

Defibrotide (defiteli) is a mixture of single-stranded oligonucleotides broken down from genomic DNA from calf lung or porcine intestinal mucosa. The oligonucleotide chain length of DF varies, the relative molecular mass ranges from 15×10³-30×10³, and its purine to pyrimidine ratio is greater than 0.85. The mechanism of action of defibrotide (defiteli) is complex and is not yet fully understood. Preclinical trials have confirmed that defibride has anti-thrombotic, profibrinolytic, anti-ischemic, anti-infective and other effects in vivo and in vitro; the recommended dose of defibrotide (defiteli) for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Give defibrotide (defiteli) for a minimum of 21 days. If signs and symptoms of hepatic VOD do not resolve after 21 days, continue defibrination until resolution of VOD or up to a maximum of 60 days. Do not coadminister defibrotide (defiteli) with other intravenous medications at the same time and in the same intravenous line.

The above are the indications of defibrinoside (defiteli sodium, defiteli) introduced to you by our Medical Companion Travel Overseas Medical Consulting Service Company, as well as its effects.